Printer Friendly

PHARMATEC ANNOUNCES INITIAL CLOSING OF PRIVATE FINANCING IN THE AMOUNT OF $1.0 MILLION

 PHARMATEC ANNOUNCES INITIAL CLOSING OF PRIVATE FINANCING
 IN THE AMOUNT OF $1.0 MILLION
 GAINESVILLE, Fla., Nov. 7 /PRNewswire/ -- Pharmatec, Inc. (NASDAQ: PHTC) today announced that it has completed an initial closing for $1.0 million of


new capital with David Blech in the first stage of a private financing that will result in a total of $5.5 million of new capital for the company.
 As previously announced, the terms of the financing provide that in exchange for $5.5 million, Pharmatec will issue 3,666,667 units of its securities. Each unit will consist of two shares of common stock and one Class A warrant. Each Class A warrant will be exercisable at a price of $1.25 for a period of six years from the date of the placement to purchase a unit consisting of one share of common stock and one Class B warrant. Each Class B warrant will be exercisable at a price of $1.75 for a period of seven years from the date of the placement to purchase one share of common stock. Although it is anticipated that David Blech and his affiliates will purchase substantially all of the units, D. Blech & Company, Incorporated will act as placement agent in connection with the financing. The company has issued Mr. Blech 666,666 units of its securities in exchange for the $1.0 million received in this initial closing. The balance of this private financing is expected to be completed in early 1992. At the completion of the financing, Mr. Blech and his affiliates will own approximately 60 percent of the outstanding stock of Pharmatec (without taking into effect any exercise of the Class A and B warrants).
 Pharmatec is a research-based drug development company specializing in two novel technologies -- a patented carrier system for enhancing the delivery of drugs to the brain and MOLECUSOL(R) brand cyclodextrins for improving the solubility, stability and delivery of drugs. D. Blech & Company, Incorporated is a New York City-based merchant banking firm specializing in biotechnology and the life sciences.
 -0- 11/7/91
 /CONTACT: Bruce N. Barron, president of Pharmatec, 904-462-1210/
 (PHTC) CO: Pharmatec, Inc. ST: Florida, New York IN: MTC SU: FNC BR-BN -- AT007 -- 2098 11/07/91 09:59 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 7, 1991
Words:375
Previous Article:STARSTREAM COMMUNICATIONS GROUP ANNOUNCES DISTRIBUTION AGREEMENT WITH WARNER MUSIC INTERNATIONAL
Next Article:ANALOG DEVICES CREATES NEW SENIOR MANAGEMENT TEAM
Topics:


Related Articles
PHARMATEC ANNOUNCES FINAL CLOSING OF PRIVATE FINANCING IN THE AMOUNT OF $5.5 MILLION WITH DAVID BLECH
PHARMOS AND PHARMATEC APPOINT NEW PRESIDENT & COO, CFO
PHARMOS COMPLETES $65 MILLION MERGER OF PHARMATEC; TO FOCUS EXPANDED TECHNOLOGY BASE ON DEVELOPMENT/COMMERCIALIZATION OF DRUGS FOR EYES,BRAIN
PHARMOS COMPLETES $5 MILLION ACQUISITION OF XENON VISION; NEWLY MERGED COMPANY CONTINUES EXPANSION OF TECHNOLOGY BASE
Eurand Acquires Pharmatec.
MEDTOX Scientific Completes $5.5 Million Financing; Initial Financing (July 31 Close) Increased by $1 Million.
Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $25 Million of Convertible Senior Notes.
Incentra Solutions Receives $1.4 Million From Additional Closings in Convertible Note Financing; Total Proceeds to Date Equal $2.4 Million.
Pioneer Announces Closing of Sale of $120,000,000 of 2.75% Convertible Senior Subordinated Notes Due 2027 and Redemption of Remaining 10% Senior...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters